Levodopa

teratocarcinoma-derived growth factor 1 pseudogene 4 ; Homo sapiens







12 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 8440292 Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. 1993 1
2 1571080 Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. 1992 1
3 1865161 Sinemet (CR4): an open-label study in moderately severe Parkinson's disease. 1991 Aug 1
4 2340838 Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. 1990 1
5 2340841 Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'. 1990 1
6 2555090 Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study. 1989 3
7 2682215 Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. 1989 2
8 2685650 Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. 1989 Nov 1
9 2709040 Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. 1989 Jan 1
10 3290706 Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. 1988 Jul 1
11 3574696 Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). 1987 May 1
12 3658164 Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. 1987 Oct 3